Durvalumab/Osimertinib Mesylate

N/A

Report date: 2026/04/29 17:37:25

Base Information

Drug NameDurvalumab/Osimertinib Mesylate
Drug Alias NameDurvalumab/OsimertinibOsimertinib Mesylate/Durvalumab
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed death-ligand 1 blockersEpidermal growth factor receptor erbB1 antagonistsEGFR T790M inhibitors
TargetsProgrammed death-ligand 1Epidermal growth factor receptor erbB1EGFR T790M
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes DurvalumabOsimertinib Mesylate
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedimmune Llc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A